VivoSeq
Other

Cholesterol

1

Pipeline Programs↗

11

Active Trials↗

19

Companies Involved↗

Cholesterol is an early-stage landscape with 1 program across 19 companies. The most active players are Eli Lilly, Daiichi Sankyo, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalM

Marea Therapeutics

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

STX-1150

Monash University

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

100

clinical trials

Completed73 · 73%
Recruiting10 · 10%
Terminated10 · 10%
Unknown status5 · 5%
Active, not recruiting1 · 1%
Withdrawn1 · 1%

Clinical Trials

Trial Activity

100 trials

Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Recruiting·NNYU Langone Health·Phase 4·NCT05641753·125 enrolled
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
Recruiting·HHenan Institute of Cardiovascular Epidemiology·Phase 4·NCT05613426·330 enrolled
The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients
Recruiting·IIndonesia University·Phase 4·NCT06903546·64 enrolled
Role of A2A Receptor in Hypercholesterolemic Patients
Recruiting·AAssistance Publique Hopitaux De Marseille·N/A·NCT05017649·150 enrolled
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Recruiting·MMarea Therapeutics·Phase 2·NCT07199309·30 enrolled
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
Recruiting·—·Phase 1·NCT04532489·6 enrolled
A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
Recruiting·—·Phase 3·NCT07012629·1,652 enrolled
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
Recruiting·—·Phase 1·NCT04546126·24 enrolled
A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
Recruiting·MMonash University·Phase 1·NCT07428473·64 enrolled
Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City: A Pilot Study
Recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT07556354·30 enrolled
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Active, not recruiting·MMarea Therapeutics·Phase 2·NCT07028749·216 enrolled
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
Completed·—·Phase 3·NCT00328523·1,496 enrolled
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 4·NCT00754039·129 enrolled
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
Completed·—·Phase 4·NCT00762164·34 enrolled
A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)
Completed·—·Phase 3·NCT00652301·40 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)